Effects of intravenous streptokinase and CLS 2210 (calcium dobesilate) on the biochemical markers of early acute myocardial infarction: A historic comparison with both studies

L. Szlavy, I. Repa, I. Lengye, L. Lamboy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In a previous double-blind, randomized study, CLS 2210 (a new formulation of calcium dobesilate) or placebo was administered by intravenous infusion to 41 patients having their first acute myocardial infarction. In the present study 19 comparable patients were treated intravenously with streptokinase under identical conditions and the results compared with those from the previous study. In all patients administration was begun within three hours of onset of symptoms and continued over seventy-two hours. Blood samples were taken for the measurement of serum activity of creatine kinase and its isoenzyme MB, and the serum and urinary concentrations of myoglobin and glycosaminoglycans were also measured. The purpose of this study was to determine the effects of CLS 2210, placebo, and streptokinase on these biochemical markers of acute myocardial infarction, thereby assessing their actions in limiting myocardial necrosis. In the CLS 2210-treated patients, the levels of serum creatine kinase and serum and urinary myoglobin were significantly lower than in the placebo patients throughout the seventy-two hours (p = 0.01, 0.005, 0.004 respectively). The levels of creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the placebo patients but fell below placebo levels between the fortieth and fifty-fifth hours, respectively (p = 0.89, 0.02). Only the glycosaminoglycan urinary concentrations were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). The values for the six variables investigated showed no statistically significant difference between placebo and streptokinase. These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, probably by the same mechanisms of action (principally, improved cardiac lymphatic drainage) that have been observed in previous animal studies. Combination therapy with thrombolytic agents may, therefore, be advocated, since they exert their protective effect by other mechanisms.

Original languageEnglish
Pages (from-to)741-747
Number of pages7
JournalAngiology
Volume43
Issue number9
Publication statusPublished - 1992

Fingerprint

Calcium Dobesilate
Streptokinase
Biomarkers
Myocardial Infarction
Placebos
Glycosaminoglycans
Serum
Myoglobin
Creatine Kinase
MB Form Creatine Kinase
Fibrinolytic Agents
CLS 2210
Double-Blind Method
Intravenous Infusions
Isoenzymes
Drainage
Necrosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{c17238f4bcb14307a2892ea4acf31566,
title = "Effects of intravenous streptokinase and CLS 2210 (calcium dobesilate) on the biochemical markers of early acute myocardial infarction: A historic comparison with both studies",
abstract = "In a previous double-blind, randomized study, CLS 2210 (a new formulation of calcium dobesilate) or placebo was administered by intravenous infusion to 41 patients having their first acute myocardial infarction. In the present study 19 comparable patients were treated intravenously with streptokinase under identical conditions and the results compared with those from the previous study. In all patients administration was begun within three hours of onset of symptoms and continued over seventy-two hours. Blood samples were taken for the measurement of serum activity of creatine kinase and its isoenzyme MB, and the serum and urinary concentrations of myoglobin and glycosaminoglycans were also measured. The purpose of this study was to determine the effects of CLS 2210, placebo, and streptokinase on these biochemical markers of acute myocardial infarction, thereby assessing their actions in limiting myocardial necrosis. In the CLS 2210-treated patients, the levels of serum creatine kinase and serum and urinary myoglobin were significantly lower than in the placebo patients throughout the seventy-two hours (p = 0.01, 0.005, 0.004 respectively). The levels of creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the placebo patients but fell below placebo levels between the fortieth and fifty-fifth hours, respectively (p = 0.89, 0.02). Only the glycosaminoglycan urinary concentrations were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). The values for the six variables investigated showed no statistically significant difference between placebo and streptokinase. These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, probably by the same mechanisms of action (principally, improved cardiac lymphatic drainage) that have been observed in previous animal studies. Combination therapy with thrombolytic agents may, therefore, be advocated, since they exert their protective effect by other mechanisms.",
author = "L. Szlavy and I. Repa and I. Lengye and L. Lamboy",
year = "1992",
language = "English",
volume = "43",
pages = "741--747",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Effects of intravenous streptokinase and CLS 2210 (calcium dobesilate) on the biochemical markers of early acute myocardial infarction

T2 - A historic comparison with both studies

AU - Szlavy, L.

AU - Repa, I.

AU - Lengye, I.

AU - Lamboy, L.

PY - 1992

Y1 - 1992

N2 - In a previous double-blind, randomized study, CLS 2210 (a new formulation of calcium dobesilate) or placebo was administered by intravenous infusion to 41 patients having their first acute myocardial infarction. In the present study 19 comparable patients were treated intravenously with streptokinase under identical conditions and the results compared with those from the previous study. In all patients administration was begun within three hours of onset of symptoms and continued over seventy-two hours. Blood samples were taken for the measurement of serum activity of creatine kinase and its isoenzyme MB, and the serum and urinary concentrations of myoglobin and glycosaminoglycans were also measured. The purpose of this study was to determine the effects of CLS 2210, placebo, and streptokinase on these biochemical markers of acute myocardial infarction, thereby assessing their actions in limiting myocardial necrosis. In the CLS 2210-treated patients, the levels of serum creatine kinase and serum and urinary myoglobin were significantly lower than in the placebo patients throughout the seventy-two hours (p = 0.01, 0.005, 0.004 respectively). The levels of creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the placebo patients but fell below placebo levels between the fortieth and fifty-fifth hours, respectively (p = 0.89, 0.02). Only the glycosaminoglycan urinary concentrations were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). The values for the six variables investigated showed no statistically significant difference between placebo and streptokinase. These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, probably by the same mechanisms of action (principally, improved cardiac lymphatic drainage) that have been observed in previous animal studies. Combination therapy with thrombolytic agents may, therefore, be advocated, since they exert their protective effect by other mechanisms.

AB - In a previous double-blind, randomized study, CLS 2210 (a new formulation of calcium dobesilate) or placebo was administered by intravenous infusion to 41 patients having their first acute myocardial infarction. In the present study 19 comparable patients were treated intravenously with streptokinase under identical conditions and the results compared with those from the previous study. In all patients administration was begun within three hours of onset of symptoms and continued over seventy-two hours. Blood samples were taken for the measurement of serum activity of creatine kinase and its isoenzyme MB, and the serum and urinary concentrations of myoglobin and glycosaminoglycans were also measured. The purpose of this study was to determine the effects of CLS 2210, placebo, and streptokinase on these biochemical markers of acute myocardial infarction, thereby assessing their actions in limiting myocardial necrosis. In the CLS 2210-treated patients, the levels of serum creatine kinase and serum and urinary myoglobin were significantly lower than in the placebo patients throughout the seventy-two hours (p = 0.01, 0.005, 0.004 respectively). The levels of creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the placebo patients but fell below placebo levels between the fortieth and fifty-fifth hours, respectively (p = 0.89, 0.02). Only the glycosaminoglycan urinary concentrations were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). The values for the six variables investigated showed no statistically significant difference between placebo and streptokinase. These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, probably by the same mechanisms of action (principally, improved cardiac lymphatic drainage) that have been observed in previous animal studies. Combination therapy with thrombolytic agents may, therefore, be advocated, since they exert their protective effect by other mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0026630484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026630484&partnerID=8YFLogxK

M3 - Article

C2 - 1514710

AN - SCOPUS:0026630484

VL - 43

SP - 741

EP - 747

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 9

ER -